Sponsors (19)
The bill preserves existing federal restrictions on mifepristone and gives FDA/HHS short-term regulatory certainty, but at the cost of reduced access and higher burdens for patients and providers and added legal/administrative risk for federal agencies.
FDA, HHS, and health systems gain near-term regulatory certainty because the bill freezes the mifepristone REMS, preventing immediate changes and avoiding short-term regulatory uncertainty.
Women and pregnant people who prefer tighter federal controls keep the existing, more restrictive federal rules on mifepristone rather than seeing them loosened.
Women and pregnant people — especially low-income and rural patients — will likely face reduced access to medication abortion and higher travel, time, and out-of-pocket costs if stricter REMS restrictions on dispensing or telemedicine are preserved.
Clinicians, pharmacies, and health systems will have reduced flexibility to prescribe, dispense, or mail mifepristone (including via telehealth), increasing logistical burdens and potentially disrupting care delivery.
HHS and FDA may face additional legal and administrative costs and litigation risk defending the reversal and the statutory freeze, imposing burdens on federal agencies (and potentially taxpayers).
Based on analysis of 2 sections of legislative text.
Nullifies the FDA's January 2023 changes to the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone and bars the Department of Health and Human Services (including FDA) from adopting, implementing, or enforcing any REMS provision for mifepristone that is substantially similar to those January 2023 changes. The prohibition takes effect upon enactment and is permanent unless changed by later law, removing the regulatory authority to use those specific types of REMS modifications for mifepristone.
Introduced January 23, 2025 by Diana Harshbarger · Last progress January 23, 2025